DOSAGE: allergy or risks for resistance, those requiring

DOSAGE:                                                 

 

For the treatment of acute bacterial
sinusitis:

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!


order now

a.     
Oral dosage

1.     
Adults

·        
400 mg PO for
10 days once daily.

·        
In cases where
alternative treatment options cannot be used Moxifloxacin should only be used, Due
to the risk for serious and potentially permanent side effects associated with
fluoroquinolone antibiotics.

·        
In patients
with beta-lactam allergy or risks for resistance, those requiring
hospitalization, or patients who failed initial therapy Clinical practice
guidelines recommend treating for 5 to 7 days as alternative therapy

b.     
Intravenous dosage

1.     
Adults

·        
400 mg IV for
10 days once daily.

·        
In cases where
alternative treatment options cannot be used Moxifloxacin should only be used,
Due to the risk for serious and potentially permanent side effects associated with
fluoroquinolone antibiotics.

·        
In patients
with beta-lactam allergy or risks for resistance, those requiring
hospitalization, or patients who failed initial therapy Clinical practice
guidelines recommend treating for 5 to 7 days as alternative therapy

 

 

For the treatment of acute bacterial
exacerbation of chronic bronchitis:

a.     
Oral dosage

1.     
Adults:

·        
400 mg PO once
daily for 5 days.

·        
In cases where
alternative treatment options cannot be used Moxifloxacin should only be used,
Due to the risk for serious and potentially permanent side effects associated with
fluoroquinolone antibiotics.

 

b.     
Intravenous dosage

1.     
Adults

·        
400 mg IV once
daily for 5 days.

·        
In cases where
alternative treatment options cannot be used Moxifloxacin should only be used,
Due to the risk for serious and potentially permanent side effects associated with
fluoroquinolone antibiotics.

 

For the treatment of mild to
moderate community-acquired pneumonia (CAP):

a.     
Oral or Intravenous dosage

1.     
Adults

·        
400 mg PO or IV
once daily for 7—14 days.

·        
As a
monotherapy option guidelines recommend in outpatients with the presence of
comorbidities or if within the past 3 months antibiotics have been used.

·        
In combination
with a beta-lactam for hospitalized, ICU patients or in hospitalized, non-ICU
patients Moxifloxacin PO/IV is a monotherapy option.

·        
Moxifloxacin
should be given with an antipneumococcal/antipseudomonal beta-lactam and an
aminoglycoside if these patients have potential Pseudomonas aeruginosa. levofloxacin
should be used in combination with aztreonam and an aminoglycoside If the
patient has a beta-lactam allergy.

·        
If MRSA is a
potential pathogen add vancomycin or linezolid. The treatment for a minimum of
5 days is recommended by IDSA/ATS and with no more than 1 sign of clinical
instability before discontinuation for 48—72 hours the patient should be a-febrile.

 

2.     
Adolescents with skeletal maturity

·        
400 mg PO once
daily the Infectious Diseases Society of America (IDSA) recommend for CAP as an
alternative oral therapy due to Chlamydia trachomatis, Mycoplasma pneumoniae, or
Chlamydophila pneumoniae.

 

For the treatment of skin and skin
structure infections:

A.     For
uncomplicated skin and skin structure infections due to Staphylococcus aureus
(MSSA) and Streptococcus pyogenes.

a.     
Oral or Intravenous dosage

1.     
Adults >= 18 years

·        
400 mg PO or IV
for 7 days once daily.

 

B.     
For complicated skin and skin structure infections
due to Escherichia coli, Enterobacter cloacae, Staphylococcus aureus (MSSA), or
Klebsiella pneumoniae:

a.     
Oral or Intravenous dosage

2.     
Adults >= 18 years

·        
400 mg PO or IV
for 7—21 days once daily.

 

C.     
For the treatment of complicated intraabdominal
infections including polymicrobial infections such as abscesses:

a.     
Oral or Intravenous dosage

1.     
Adults >= 18 years    

·        
400 mg IV or PO
for 5—14 days once daily. When clinically indicated Therapy should start with the
IV formulation; then, switch to oral therapy.

 

D.     For the
treatment of bacterial conjunctivitis (including chlamydial conjunctivitis) due
to susceptible organisms:

a.     
Ophthalmic dosage:

1.     
Adults

·        
In each
affected eye 3 times per day Instill 1 drop (0.5% ophthalmic solution) for 7
days.

 

2.     
Infants, Children, and Adolescents

·        
In each
affected eye 3 times per day Instill 1 drop (0.5% ophthalmic solution) for 7
days.

 

3.     
Neonates

·        
In each
affected eye 3 times per day Instill 1 drop (0.5% ophthalmic solution) for 7
days.

 

For the treatment of plague,
including pneumonic and septicemic plague, and plague prophylaxis due to
susceptible isolates:

a.     
Oral or Intravenous dosage

1.     
Adults

·        
400 mg PO or IV
for 10—14 days once daily.

 

For the treatment of tuberculosis
infection caused by Mycobacterium tuberculosis in combination with other
antituberculosis agents as a second line agent:

 

a.     
Oral or Intravenous dosage

1.     
Adults

·        
400 mg IV or PO
once daily.

·        
 The WHO organization recommends 7.5—10 mg/kg
IV or PO daily for patients 2 log CFU/mL of blood), or in the absence of successful
antiretroviral therapy.

·        
For patients
with moderate to severe immune reconstitution inflammatory syndrome (IRIS) adjunctive
steroids can be considered.

·        
Treatment duration
is depended on clinical response, but should continue for greater than equal to
12 months.